-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recently, the official website of NMPA showed that Yichang Renfu Pharmaceutical's registration application for category 3 generic drug "Midazolam Oral Solution" has changed to "Under Approval", and it is expected to be approved soon, becoming the first oral midazolam in China.
According to the Insight database, the drug was officially included in the priority review and approval in November 2019, and is suitable for sedation, anti-anxiety, and amnesia of pediatric patients before diagnosis, treatment, endoscopic surgery, or induction of anesthesia.
Midazolam is a sedative and hypnotic drug.
Midazolam oral solution has been on the market for many years abroad.
According to the Insight database, among the domestic midazolam oral solution preparations, Yichang Renfu Pharmaceutical Co.
Image source: Insight database (https://db.
Image source: Insight database (https://db.
dxy.
cn/v5/home)